根据最新的财务报表(Form-10K),BICO Group AB (publ) 的总资产为 $0,净亏损为 $0
BCCOY 的关键财务比率是什么?
BICO Group AB (publ) 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
BICO Group AB (publ) 的收入按细分市场或地理位置如何划分?
BICO Group AB (publ) 最大收入来源是 Life Science Solutions,在最近的收益报告中收入为 1,009,100,000。就地区而言, United States 是 BICO Group AB (publ) 的主要市场,收入为 1,162,800,000。
BICO Group AB (publ) 是否盈利?
否,根据最新的财务报表,BICO Group AB (publ) 的净亏损为 $0
BICO Group AB (publ) 有负债吗?
否,BICO Group AB (publ) 的负债为 0
BICO Group AB (publ) 的流通股有多少?
BICO Group AB (publ) 的总流通股为 0
关键数据
前收盘价
$0.3688
开盘价
$0.65
当日区间
$0.3688 - $0.65
52周范围
$0.3688 - $0.8
交易量
6.0K
平均成交量
20
股息收益率
--
每股收益(TTM)
-0.55
市值
$101.8M
什么是 BICO GROUP AB?
BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 589 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.